Page 19 - ஒருங்கிணைப்பு ஆஃப் பொது ஆரோக்கியம் அவசரம் செயல்பாடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஒருங்கிணைப்பு ஆஃப் பொது ஆரோக்கியம் அவசரம் செயல்பாடுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஒருங்கிணைப்பு ஆஃப் பொது ஆரோக்கியம் அவசரம் செயல்பாடுகள் Today - Breaking & Trending Today

GSK expands its clinical trial manufacturing capacity at dedicated CGT facility in UK

GSK expands its clinical trial manufacturing capacity at dedicated CGT facility in UK
Cell and Gene Therapy Catapult (CGT Catapult) says that GSK will leverage its Stevenage facility to perform GMP cell processing and accelerate its cell and gene therapy pipeline for clinical trials.
Through this agreement, GSK is looking to improve its GMP cell processing network to advance its early stage pipeline and streamline technical transfer.
“The move by a leading pharmaceutical company like GSK to establish ATMP manufacturing capabilities at the CGT Catapult facility in Stevenage highlights the UK’s globally leading position for large and smaller organizations alike to develop, manufacture and deliver cell and gene therapies,” said Matthew Durdy, CEO, CGT Catapult. ....

United Kingdom , Rentschler Biopharma , Matthew Durdy , Advanced Therapy Medicinal Products , Clinical Development , Clinical Evolution , Phasei Ii , Phase Iii Iv , Cell And Gene Therapy , ஒன்றுபட்டது கிஂக்டம் , மருத்துவ வளர்ச்சி , மருத்துவ பரிணாமம் , கட்டம் ஈயீ இவ் , செல் மற்றும் கீந் சிகிச்சை ,

Saama, Oracle partner on integrated clinical trial technology

Saama, Oracle partner on integrated clinical trial technology
Saama’s range of Smart applications will be integrated with the Oracle Health Sciences Clinical One platform to help users accelerate drug development.
Saama Technologies is collaborating with Oracle to integrate Saama’s smart applications with the Oracle Health Sciences Clinical One platform. The collaboration is intended to enable pharmaceutical companies and their research partners to harness artificial intelligence (AI)-driven insights to expedite clinical trials.
Saama chief strategy officer Sagar Anisingaraju spoke with Outsourcing-Pharma about the technological integration, and how advanced technologies like artificial intelligence and machine learning are transforming research. ....

Sagar Anisingaraju , Ai Research Labs , Oracle Health Sciences Clinical , Saama Technologies , Oracle Health Sciences Clinical One , Smart Automapper , Smart Data Quality , Clinical Development , Clinical Evolution , Data Management , Phasei Ii , Phase Iii Iv , Artificial Intelligence , Clinical Trials Software , ஐ ஆராய்ச்சி ஆய்வகங்கள் , ஆரக்கிள் ஆரோக்கியம் அறிவியல் மருத்துவ , சாம தொழில்நுட்பங்கள் , ஆரக்கிள் ஆரோக்கியம் அறிவியல் மருத்துவ ஒன்று , புத்திசாலி தகவல்கள் தரம் , மருத்துவ வளர்ச்சி , மருத்துவ பரிணாமம் , தகவல்கள் மேலாண்மை , கட்டம் ஈயீ இவ் , செயற்கை உளவுத்துறை , மருத்துவ சோதனைகள் மென்பொருள் ,

Partners& creates northern hub with fresh deal

Insurance Age
Subscriptions
Subscriptions
Partners& has bought Bolton-based insurance broker Ives & Taylor for an undisclosed sum.
The business, which was launched by ex Jelf boss Phil Barton and former Bluefin CEO Stuart Reid last April, said the move was in line with its strategy to build a hub in the North of England.
It noted that Ives & Taylor brings commercial lines, professional indemnity and private clients business to the Partners& portfolio. The broker was established in Bolton in 1965 and employs 13 people.
Partners& was
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content. ....

Phil Barton , Stuart Reid , Partners Amp , Mergers Amp Acquisitionsm Ampa , பில் பார்டன் , ஸ்டூவர்ட் ரீட் , கூட்டாளர்கள் ஆம்ப் ,

Gilead, Merck to team up on potential HIV combo treatment

Gilead, Merck to team up on potential HIV combo treatment
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
Gilead Sciences and Merck have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV. The intended solutions will combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people with HIV.
Islatravir and lenacapavir are potentially first-in-class medicines in late-stage clinical trials, with significant clinical data generated for both to date. Each of the medicines reportedly has a long half-life and has demonstrated activity at low dosages in clinical studies, which support development as an investi ....

Kenneth Frazier , Gilead Sciences , Danielo Day , Clinical Development , Preclinical Research , Mergers And Acquisitions , Clinical Evolution , Phasei Ii , Phase Iii Iv , கெநெத் ப்ராஜிேர் , கிலியட் அறிவியல் , மருத்துவ வளர்ச்சி , இணைப்புகள் மற்றும் கையகப்படுத்துதல் , மருத்துவ பரிணாமம் , கட்டம் ஈயீ இவ் ,

CDP versus DMP: What's the difference?

Data types: First party data management with little third party data.
Profile identifier: Primarily keyed on tangible customer attributes (PII) – customer ID, name, email, address etc.
Data retention: Typically long retention periods to enable analytics over customer life time.
DMP features
Data types: Third party data management with little (anonymised) first party data.
Profile identifier: Primarily keyed on anonymous digital identifiers (non-PII) – cookie ID, IDFA, etc.
Data retention: Relatively short retention periods because primary use cases are ad targeting.
To learn more about CDP versus DMP check out this report.
Five reasons to consider a CDP
1.Storing first party data, including PII ....

Customer Data Platform , Data Management Platforms , Ad Targeting , Data Management , Customer Relationship , Customer Experience , வாடிக்கையாளர் தகவல்கள் நடைமேடை , தகவல்கள் மேலாண்மை தளங்கள் , தகவல்கள் மேலாண்மை , வாடிக்கையாளர் உறவு , வாடிக்கையாளர் அனுபவம் ,